Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.


Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.

LHA ID: 84H299KF04-7

PubMed ID: 33042584

Projects: Genetical Statistics and Systems Biology

Publication type: Journal article

Journal: Card Fail Rev

Human Diseases: No Human Disease specified

Citation: Card Fail Rev. 2020 Sep 28;6:e24. doi: 10.15420/cfr.2019.19. eCollection 2020 Mar.

Date Published: 12th Oct 2020

Registered Mode: by PubMed ID

Authors: S. Rosch, K. P. Rommel, M. Scholz, H. Thiele, P. Lurz

help Submitter

Views: 187

Created: 3rd Nov 2020 at 10:40

help Tags

This item has not yet been tagged.

help Attributions


Related items

Powered by
Copyright © 2008 - 2021 The University of Manchester and HITS gGmbH
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig

By continuing to use this site you agree to the use of cookies